I have no intention of even implicitly commenting on the legality of the ongoing incarceration of Douglas Devananda. I’ve no ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla ...

At Tesla's (NASDAQ: TSLA) recent annual general meeting, CEO Elon Musk said the company is gearing up to start production of ...